Oral News and Research

RSS

FDA approves Mylan Pharmaceuticals' generic NuLytely laxative

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution (with Flavor Packs), the generic version of Braintree Laboratories' NuLytely® laxative.

8 Apr 2010

Baxa releases DoseEdge TPN for automated TPN production

Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations and increase patient safety, today announced the release of DoseEdge TPN, the industry's first product for completely managing the workflow for automated TPN production.

8 Apr 2010

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

7 Apr 2010

Updates from Phase I/IIa clinical trial of DIABECELL treatment in insulin-dependent diabetics

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today provided a penultimate update regarding the three-year follow up of its Phase I/IIa clinical trial in Russia of its DIABECELL® treatment in insulin-dependent diabetics.

7 Apr 2010

Major social science study to accompany Bovine TB BVDP

A major social science study to accompany the Government's Bovine TB Badger Vaccine Deployment Project, to be launched this summer [2010], will be led by a researcher from the University of the West of England, with colleagues from the Countryside and Community Research Institute, in collaboration with Exeter and Cardiff Universities, Drew Associates Limited, the Veterinary Laboratories Agency and the Food and Environment Research Agency.

7 Apr 2010

ESC heart failure meeting encourages audience interaction

"Delegates attending the meeting will get real insights into what's new in heart failure," said Professor Stefan Anker, chairman of the Heart Failure Congress Scientific Committee. "In what's the biggest international stand-alone meeting dedicated to heart failure, there'll be lots of hot of the press news. The very fact that 12 late breaking clinical trial updates are being presented at the meeting demonstrates how bright the future is in heart failure."

7 Apr 2010

Research shows direct link between dental health and general health

Research has shown a direct link between the health of our mouths and our general health. Periodontal (gum) disease may increase adult risk of diseases such as heart, stroke, diabetes and respiratory diseases. Tooth and gum disease and is one of the most common dental problems of older adults.

7 Apr 2010

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Genta Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted the Company's request for "Fast Track" designation of tesetaxel for treatment of patients with advanced gastric cancer. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

7 Apr 2010

Investment report on Keryx Biopharmaceuticals from BeaconEquity.com

BeaconEquity.com announces an investment report featuring Keryx Biopharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

StockPreacher.com releases investment report on Repros Therapeutics

StockPreacher.com announces an investment report featuring Repros Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

Electronic nose may help identify asthma in patients: CHEST

New evidence shows that an "electronic nose" containing an array of gas sensors may have the ability to identify asthma in patients. Researchers from Italy compared the diagnostic performance of the electronic nose with lung function tests and fraction of exhaled nitric oxide in seven patients with asthma and seven healthy subjects.

6 Apr 2010

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

Results from a recent survey of 400 Sjogren's syndrome patients showed that half of those surveyed experienced common symptoms such as dry mouth or dry eyes for three or more years before receiving an accurate diagnosis from a healthcare professional.

6 Apr 2010

New muco-adhesive patch may help treat oral disorders

A newly developed time-released muco-adhesive patch for treating oral health conditions, including the widespread condition of dry mouth (xerostomia), has been shown to be more effective than a leading oral rinse, according to a newly-published study.

6 Apr 2010

New study to compare Botox against oral medications for urge incontinence in women

A new study is underway at Loyola University Health System to compare botulinum toxin A or Botox® versus common oral medications for urge incontinence in women. Urge incontinence is urinary incontinence with a strong or sudden need to urinate. Millions of women suffer in silence each day from this condition.

6 Apr 2010

SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

Drug discovery company, SCYNEXIS, Inc. today announced that multiple abstracts related to the Company's cyclophilin inhibitor, SCY-635, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria, April 14-18, 2010.

6 Apr 2010

Rice University's nano-bio-chip 93% specific in detecting patients with premalignant lesions

The gentle touch of a lesion on the tongue or cheek with a brush can help detect oral cancer with success rates comparable to more invasive techniques, according to preliminary studies by researchers at Rice University, the University of Texas Health Science Centers at Houston and San Antonio and the University of Texas M.D. Anderson Cancer Center.

6 Apr 2010

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010

Request for lift of full clinical hold on Proellex program

Repros Therapeutics Inc. today announced that the Company has requested a lift of the full clinical hold on its oral drug Proellex® being developed for the treatment of uterine fibroids and endometriosis. On August 4, 2009, the FDA noted that further testing of Proellex® was placed on full clinical hold due to findings of serious adverse events associated with liver toxicity.

5 Apr 2010

WCU: Dental Hygiene Clinic to offer free dental hygiene services at Anaheim campus

West Coast University has announced that the Dental Hygiene Clinic at its Anaheim campus will offer the public free dental hygiene services ranging from oral inspection and risk assessment, to digital and traditional imaging (X-rays), to preventative therapies and non-surgical periodontal therapy (cleanings).

5 Apr 2010

Oral News and Research

FDA approves Mylan Pharmaceuticals' generic NuLytely laxative

Baxa releases DoseEdge TPN for automated TPN production

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Updates from Phase I/IIa clinical trial of DIABECELL treatment in insulin-dependent diabetics

Major social science study to accompany Bovine TB BVDP

ESC heart failure meeting encourages audience interaction

Research shows direct link between dental health and general health

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Investment report on Keryx Biopharmaceuticals from BeaconEquity.com

StockPreacher.com releases investment report on Repros Therapeutics

Electronic nose may help identify asthma in patients: CHEST

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

New muco-adhesive patch may help treat oral disorders

New study to compare Botox against oral medications for urge incontinence in women

SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

Rice University's nano-bio-chip 93% specific in detecting patients with premalignant lesions

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Request for lift of full clinical hold on Proellex program

WCU: Dental Hygiene Clinic to offer free dental hygiene services at Anaheim campus

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News